Galmed Pharmaceuticals Ltd.
GLMD
$1.07
$0.1111.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.17% | -126.00% | 65.60% | -67.66% | -71.05% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.33% | 667.95% | -95.73% | 1,422.50% | 0.00% |
| Change in Net Operating Assets | -110.35% | 545.39% | 75.98% | -187.74% | 827.17% |
| Cash from Operations | -52.60% | -8.65% | 40.73% | -75.02% | -10.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.93% | -1,877.92% | 93.49% | -630.25% | -134.91% |
| Cash from Investing | 99.93% | -1,877.92% | 93.49% | -630.25% | -134.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.21% | 298.61% | 237.95% | -94.63% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.21% | 298.61% | 237.95% | -94.63% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -932.83% | 70.69% | 102.29% | -175.37% | 1,693.87% |